In May 2022, Sun Pharmaceutical Industries Limited Announced that one of its Wholly Owned Subsidiaries Plans to Launch a First-in-Class Oral Drug, Bempedoic acid, in India for Reducing Low-Density Lipoprotein (LDL) Cholesterol

According to the World Health Organization (WHO) report in February 2022, Cervical cancer is the fourth most common cancer among women globally, with an estimated 604 000 new cases and 342 000 deaths in 2020. About 90% of the new cases and deaths worldwide in 2020 occurred in low- and middle-income countries. According to a new United Nations report, up to 1 billion people, nearly one in six of the world's population, suffer from neurological disorders, from Alzheimer's and Parkinson's disease, strokes, multiple sclerosis, and epilepsy to migraine, brain injuries and neuro-infections, with some 6.8 million dying of the maladies each year       

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-lipid-market

Global Lipids Market is expected to reach USD 23,307.43 million by 2030 from USD 12,264.66 million in 2022, growing at a CAGR of 8.4% in the forecast period of 2023 to 2030. The global lipids market is growing in the forecast year due to the rise in market players and the availability of advanced methodology in the drugs production. Along with this, manufacturers are engaged in R&D activity for launching novel drugs in the market. The increasing drug development is further boosting the market growth. However, the high cost for lipid synthesis and stringent government rules and regulations for drug approvals might hamper the growth of the global lipids market in the forecast period.                

Lipids Market

The increasing prevalence and incidence of chronic diseases across the world will drive the market's growth rate

The encumbrance of chronic disease is briskly increasing across the globe. According to the WHO (World Health Organization), in 2021, the contribution of chronic disease was about 60%, which accounted for the number of deaths. In most Western countries, the major reason behind the increasing number of chronic diseases is the continuous increase in the aged population. Thus, in conclusion, the rise in the number of chronic diseases such as cardiovascular diseases, neurological disorders, and various other chronic diseases has led to an increase in the demand for various medicinal drugs that will drive the growth of the global lipids market in the coming years.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Natural Lipids and Synthetic Lipids), Lipid System (Neutral Lipids, Bacterial Lipids, Fluorescent Lipids, Bioactive Lipids, Polymerizable Lipids, Headgroup Modified Lipids, and Others), Delivery System (Liposomes, Solid Lipid Nanoparticles, Nanostructures Lipid Carrier, Niosomes, Transferosomes, and Others), Source (Egg Yolk, Soyabean, Non-GMO Soyabean, Purified Oils, Purified Fatty Acids, and Others), End User (Pharmaceutical Industries, Biotechnology Industries, Academic and Research Institutes, Cosmetic Industries and Others), Distribution Channel (Direct Tender, Retail Sales and Others)

Countries Covered

U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

Market Players Covered

Alnylam Pharmaceutical, Inc. (U.S.), Croda International Plc. (U.K.), Moderna Inc. (U.S.), BioNTech SE. (U.S.), Pfizer Inc. (U.S.), Evonik Industries AG (Germany), Lipoid GmbH (Germany), Matreya LLC (U.S.), VAV Life Sciences Pvt Ltd. (India), Curia Global Inc. (U.S.), Cargill, Incorporated (U.S.), CD Bioparticles (U.S.), Merck KGaA (Germany), CHEMI S.p.A. (Italy), DSM (Netherlands), BASF SE (Germany), Tokyo Chemical Industry Co., Ltd. (Japan), Stepan Company (U.S.), and Kerry Group plc (Ireland) among others

Data Points Covered in the Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework

Segment Analysis:

Global lipids market is categorized into six notable segments such as type, lipid systems, delivery system, source, end user and distribution channel.

  • On the basis of type, the global lipids market is segmented into natural lipids and synthetic lipids. In 2023, natural lipids segment is expected to dominate the global lipids market with 56.92% market share as this type of lipids is more prevalent in various regions.
  • On the basis of lipid systems, the global lipids market is segmented into neutral lipids, bacterial lipids, fluorescent lipids, bioactive lipids, polymerizable lipids, headgroup modified lipids and others . In 2023, bioactive lipids segment is expected to dominate the global lipids market with 32.52% market share as this type of lipid system has more demand for the drug development process.
  • On the basis of delivery system, the global lipids market is segmented into liposomes, solid lipid nanoparticles, nanostructurers lipid carrier, niosomes, transferosomes and others. In 2023, liposomes segment is expected to dominate the global lipids market with 35.56% market share as this delivery systmes is mostly preferred and is more prevalent in various regions.
  • On the basis of source, the global lipids market is segmented into eggyolk, soyabean, non-GMO soyabean, purified oils, purified fatty acids and others . In 2023, purified fatty acids segment is expected to dominate the global lipids market with 40.02% market share as lipids taken from this source have various applications and advanatages in drug delivery systems.
  • On the basis of end user, the global lipids market is segmented into pharmaceutical industries, biotechnology industries, academic and research institutes, cosmetic industries and others. In 2023, pharmaceutical industries segment is expected to dominate the global lipids market with 36.20% market share as this type of end users usually prefers in the pharmaceutical lipids market.

The pharmaceutical industries segment will dominate the end user segment of the lipids market

The pharmaceutical industries segment will emerge as the dominating segment end user segment. This is because of the growing number of pharmaceutical industries in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.

  • On the basis of distribution channel, the global lipids market is segmented into direct tender, retail sales and others. In 2023, direct tender segment is expected to dominate the global lipids market with 54.49% market share as this distribution channel is mostly preferred in this market.

The direct tender segment will dominate the distribution channel segment of the lipids market

The direct tender segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.

Major Players         

Data Bridge Market Research recognizes the following companies as the market players in market: Alnylam Pharmaceutical, Inc. (U.S.), Croda International Plc. (U.K.), Moderna Inc. (U.S.), BioNTech SE. (U.S.), Pfizer Inc. (U.S.), Evonik Industries AG (Germany), Lipoid GmbH (Germany), Matreya LLC (U.S.), VAV Life Sciences Pvt Ltd. (India), Curia Global Inc. (U.S.), Cargill, Incorporated (U.S.), CD Bioparticles (U.S.), Merck KGaA (Germany), CHEMI S.p.A. (Italy), DSM (Netherlands), BASF SE (Germany), Tokyo Chemical Industry Co., Ltd. (Japan), Stepan Company (U.S.), and Kerry Group plc (Ireland).

Lipids Market

Market Development

  • In May 2021, Merck scaled up the production of lipids to meet patients' demands during COVID-19. The company launched a new, high-purity synthetic cholesterol product.
  • Evonik invested in the short-term growth of its specialty lipids production at its Hanau and Dossenheim locations in Germany, which supplied two of the four lipids for the Pfizer/BioNTech vaccine. According to Spencer, the first batches were delivered to BioNTech in April, 2021 months ahead of schedule.
  • In May 2022, Sun Pharmaceutical Industries Limited announced that one of its wholly-owned subsidiaries plans to launch a first-in-class oral drug, Bempedoic Acid, in India for reducing low-density lipoprotein (LDL) cholesterol. The company will launch the drug under the brand name "Brillo." Brillo is a first-in-class drug with a new mechanism of action compared to the currently available lipid-lowering agents.  

Regional Analysis

Geographically, the countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

As per Data Bridge Market Research analysis:

North America is the dominant region in lipids market during the forecast period 2023 to 2030

North America lipids market is expected to grow due to the rise in chronic diseases owing to high demand for pharmaceutical drugs and rising demand for lipids in different industries are expected to drive the regional market in the forecasted period.

Asia-Pacific is estimated to be the fastest growing region in lipids market the forecast period 2023 to 2030

Asia-Pacific is projected to observe significant growth during the forecast period in the market due to the increasing demand for lipids in different industries expected to drive the regional market in the forecasted period.

COVID-19 Impact

The pandemic of COVID-19 had a significant impact on the pharmaceutical and nutraceutical industries. The COVID-19 has positively affected the market. The demand for COVID-19 vaccine was on the great demand and the positive point here is that the lipid is majorly used in the vaccine production. Thus COVID-19 affected lipids market positively. The industry is also projected to witness a good growth rate post lockdown relaxations and release of movement restrictions. 

For more detailed information about the lipids market, visit: https://www.databridgemarketresearch.com/reports/global-lipid-market